Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes.
SGLT-2 inhibitor
lung cancer
pharmacoepidemiology
type 2 diabetes
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
revised:
12
02
2024
received:
19
10
2023
accepted:
16
02
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
aheadofprint
Résumé
We sought to determine whether the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of incident lung cancers among patients with type 2 diabetes. We assembled a new-user, active comparator cohort of SGLT-2 inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor users using the United Kingdom Clinical Practice Research Datalink. We fit Cox proportional hazards models with propensity score fine stratification weighting to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) for incident lung cancer. Crude incidence rates were 0.94 per 1000 person-years among 69 675 SGLT-2 inhibitor users followed for a median of 2.4 years and 1.45 per 1000 person-years among 151 495 DPP-4 inhibitor users followed for a median of 3.7 years. No reduced short-term risk of lung cancer was observed among SGLT-2 inhibitor users after weighting (HR 0.96, 95% CI 0.77-1.21). Further research with a longer follow-up period may be warranted.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CIHR
ID : FDN-143328
Pays : Canada
Informations de copyright
© 2024 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Abrahami D, D'Andrea E, Yin H, et al. Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. 2023;25(10):2980-2988. doi:10.1111/dom.15196
Scafoglio CR, Villegas B, Abdelhady G, et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018;10(467):eaat5933. doi:10.1126/scitranslmed.aat5933
Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res. 2001;92(8):874-879. doi:10.1111/j.1349-7006.2001.tb01175.x
Zhou J, Zhu J, Yu S-J, et al. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway. Biomed Pharmacother. 2020;132:110821. doi:10.1016/j.biopha.2020.110821
Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827-836. doi:10.1093/ije/dyv098
Wexler DJ. In: Nathan DM, Mulder JE, eds. Management of Persistent Hyperglycemia in type 2 Diabetes Mellitus. UpToDate; 2021. Accessed 12 Dec 2021. https://www.uptodate.com/contents/management-of-persistent-hyperglycemia-in-type-2-diabetes-mellitus#H27
American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Supplement 1):S98-S110. doi:10.2337/dc20-S009
Rouette J, Yin H, Yu OHY, Bouganim N, Platt RW, Azoulay L. Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes. Diabet Med. 2020;37(5):868-875. doi:10.1111/dme.14287
Alexander SPH, Fabbro D, Kelly E, et al. The concise guide to PHARMACOLOGY 2023/24: transporters. Br J Pharmacol. 2023;180(S2):S374-S469. doi:10.1111/bph.16182
Alexander SPH, Fabbro D, Kelly E, et al. The concise guide to PHARMACOLOGY 2023/24: enzymes. Br J Pharmacol. 2023;180(S2):S289-S373. doi:10.1111/bph.16181
Hicks B, Kaye JA, Azoulay L, Kristensen KB, Habel LA, Pottegård A. The application of lag times in cancer pharmacoepidemiology: a narrative review. Ann Epidemiol. 2023;84:25-32. doi:10.1016/j.annepidem.2023.05.004
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399-424. doi:10.1080/00273171.2011.568786
Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657. doi:10.1136/bmj.l5657
Willems S, Schat A, van Noorden M, Fiocco M. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator. Stat Methods Med Res. 2018;27(2):323-335. doi:10.1177/0962280216628900
Hawthorne G, Hrisos S, Stamp E, et al. Diabetes care provision in UK primary care practices. PLoS ONE. 2012;7(7):e41562. doi:10.1371/journal.pone.0041562
Williams DR, Baxter HS, Airey CM, Ali S, Turner B. Diabetes UK funded surveys of the structural provision of primary care diabetes services in the UK. Diabet Med. 2002;19(Suppl 4):21-26. doi:10.1046/j.1464-5491.19.s4.5.x
Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6(1):e010210. doi:10.1136/bmjopen-2015-010210
Strongman H, Williams R, Bhaskaran K. What are the implications of using individual and combined sources of routinely collected data to identify and characterise incident site-specific cancers? A concordance and validation study using linked English electronic health records data. BMJ Open. 2020;10(8):e037719. doi:10.1136/bmjopen-2020-037719
Lix L, Smith M, Pitz M, et al. Cancer Data Linkage in Manitoba: Expanding the Infrastructure for Research. Manitoba Centre for Health Policy, College of Medicine, Faculty of Health Sciences, University of Manitoba; 2016.